



28th October 2024

The Secretary,
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001
Scrip Code: 544250

The Secretary,
The National Stock Exchange of India Limited
C-1, Block G, Exchange Plaza
Bandra-Kurla Complex
Bandra East, Mumbai - 400 050
Symbol: SANOFICONR

Sub: Disclosure under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.

Dear Sir/Ma'am,

Pursuant to SEBI (Prohibition of Insider Trading) Regulations, please find attached the disclosure received from Opella Healthcare Participations B. V. regarding change in holding of Securities of Promoter of the Company. The Company received this disclosure from Opella Healthcare Participations B. V. on 25th October 2024 after close of Trading hours.

Kindly take the above information on record.

Thanking you,

Yours faithfully,
For **Sanofi Consumer Healthcare India Limited**

Nikunj Kumar Savaliya
Company Secretary and Compliance Officer
Membership No.: FCS 7048

Encl. a. a.

Opella.

Date: 25 October 2024

To,
Sanofi Consumer Healthcare India Limited,
3rd Floor,
Sanofi House,
CTS No. 117-B, L&T Business Park,
Saki Vihar Road, Powai,
Mumbai – 400072

Re.: Disclosure under Regulation 7(2)(a) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (“PIT Regulations”).

Dear Sir / Ma’am,

We make reference to the prior intimation made by Opella Healthcare Participations BV (“Opella”) to the stock exchanges (namely BSE Limited and National Stock Exchange of India Limited) under Regulation 10(5) of the Takeover Regulations on 3 October 2024 informing about the proposed inter-se transfer of equity shares of Sanofi Consumer Healthcare India Limited (“SCHIL”), between Hoechst GmbH and Sanofi (then promoters of SCHIL, collectively the “Sellers”) and Opella (“Acquirer”/“Buyer”) to be undertaken in one or more tranches.

The first tranche of the above-mentioned transaction was completed between Hoechst GmbH and Opella on 10 October 2024 wherein Hoechst GmbH transferred 1,39,04,722 equity shares of SCHIL (representing 60.37% of the equity share capital of SCHIL) to Opella.

We now wish to inform you that we, Opella, entered into a Share Transfer Agreement (“STA”) on 18 October 2024 with Sanofi for the inter-se transfer of the 4,865 equity shares of SCHIL (representing 0.02% of the equity share capital of SCHIL) held by Sanofi in SCHIL to Opella, and the same falls under the exemption from making an open offer as provided under Regulation 10(1)(a)(iii) of the Takeover Regulations. Pursuant to the STA, we, Opella have acquired 4,865 equity shares in SCHIL (representing 0.02% of the equity share capital of SCHIL) from Sanofi on 25 October 2024.

Please find enclosed the disclosure in respect of the aforesaid sale.

Opella.

For and on behalf of Opella



Authorized Signatory

Name: Peter Brouwer

Designation: Director

Date: 25 October 2024

Place: Amsterdam, the Netherlands

Opella.

SEBI (Prohibition of Insider Trading) Regulations, 2015
[Regulation 7 (2) read with Regulation 6(2) – Continual Disclosure]

Name of the company: Sanofi Consumer Healthcare India Limited ("SCHIL")

ISIN of the company: INE0UOS01011

Details of change in holding of Securities of Promoter, Member of the Promoter Group, Designated Person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2).

Name, PAN, & CIN/DIN, address with contact nos.	Category of Person (Promoter/member of the promoter group/designated person/Director/s/immediate relative to/others etc.)	Securities held prior to acquisition/disposal		Securities acquired/Disposed		Securities held post acquisition/disposal	Date of allotment/advice/acquisition of shares/disposal of shares, specify	Date of intimation to company	Mode of acquisition/disposal (on-market/public/rights/preferential offer/off market/Inter-se transfer, ESOPs, etc.)	Exchange on which the trade was executed
		Type of securities (For eg. Shares, Warrant, Convertible Debentures, Rights entitlements etc.)	No. and % of share holding	Type of securities (For eg. Shares, Warrant, Convertible Debentures, Rights entitlement, etc.)	Value					

Opella.

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Name: Opella Healthcare Participations BV (“Opella”)	Promoter	Equity shares	1,39,04,7 22 (60.37%)	Equity shares	4,865 (0.02%)	23,263,7 00.25	Purchase	Equity Shares	1,39,09,5 87(60.40 %)	25 October 2024	25 October 2024	25 October 2024	Inter-se transfer of equity shares (undertake in off- market) which is exempt from making an open offer under Regulation 10(1)(a)(iii) of the Securities and Exchange Board of India (Substantia l Acquisitio n of Shares and Takeovers) Regulation s, 2011.	Not applicabl e (“N.A.”)
PAN: AAECO4323P														
CIN: Not applicable														
Address: Paasheuvelweg 25, 1105 BP Amsterdam, The Netherlands														
Contact No.: +31 202453321														

Note: (i) “Securities” shall have the meaning as defined under regulation 2(1)(i) of SEBI (Prohibition of Insider Trading) Regulations, 2015.
(ii) Value of transaction excludes taxes/brokerage/any other charges

Opella.

Details of trading in derivatives on the securities of the company by Promoter, member of the promoter group, designated person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2).

Type of contract	Trading in derivatives (Specify type of contract, Futures or Options etc.)						Exchange on which the trade was executed
	Contract specifications	Buy		Sell		Number of units (contracts *lot size)	
		Notional Value	Number of units (contracts *lot size)	Notional Value	Number of units (contracts *lot size)		
16	17	18	19	20	21	22	
N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.

Note: In case of Options, notional value shall be calculated based on Premium plus strike price of options.

Opella.

For and on behalf of Opella



Authorised Signatory

Name: Peter Brouwer

Designation: Director

Date: 25 October 2024

Place: Amsterdam, the Netherlands